Articles

Child care providers, many already struggling before COVID, have been hit hard over the past two years. Plummeting demand for child care, increased cleaning and supply costs, virus safety measures and capacity restrictions created a perfect storm of stressors, said providers and experts familiar with the child care field.

To reduce hospitalization and death, pharmacists should have the same prescribing abilities as doctors for COVID anti-viral drugs Paxlovid and Lagevrio, USC School of Pharmacy
Dean Vassilios Papadopoulos writes in a new MarketWatch op-ed.

USC has received $5.8 million from Gates Ventures and the American Heart Association to launch a lab aimed at diversifying clinical trials.

A new USC Schaeffer Center paper highlights tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, that are costing patients, employers and the government billions for what should be inexpensive medicines.

Researchers observed a 23% drop in opioid prescriptions and a 27% increase in prescriptions for naloxone.

Researchers at the USC Schaeffer Center have been studying the pharmaceutical distribution system since 2016; these comments about PBMs draw on that body of research.

After believing the pandemic would be under control by Memorial Day 2021, Schaeffer Center expert Geoffrey Joyce writes why he believes COVID is nowhere near under control.

Nonresident Senior Fellow Joe Grogan argues that the FDA approval process is slowing down drug innovation.

Populations underrepresented in clinical trials face worse health outcomes that will cost the U.S. trillions of dollars over the next three decades.

As of 2021, US health care expenditures exceed $3.8 trillion. It’s no secret that health care is nearly as wasteful in spending on value defects—behaviors that needlessly reduce quality, negatively impact the patient experience, or add to total costs of care—as it is in delivering clinical benefits.